APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Metabolic Disease Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Chronic Metabolic Disease Drug Industry Research Report 2026

22 December 2025120 pages

Choose your research edition.

Industry ResearchChronic Metabolic Disease Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Metabolic Disease Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Chronic Metabolic Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Metabolic Disease Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Metabolic Disease Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Chronic Metabolic Disease Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Chronic Metabolic Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Chronic Metabolic Disease Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Chronic Metabolic Disease Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Chronic Metabolic Disease Drug include Novartis, Novo Nordisk, Merck & Co. Inc, Eli Lilly, Pfizer, GlaxoSmithKline plc, Fresenius Kabi, Daiichi Sankyo and AstraZeneca plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Chronic Metabolic Disease Drug market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Chronic Metabolic Disease Drug Market by Company

Novartis

Novo Nordisk

Merck & Co. Inc

Eli Lilly

Pfizer

GlaxoSmithKline plc

Fresenius Kabi

Daiichi Sankyo

AstraZeneca plc

Torrent Labs

Regeneron Pharmaceuticals

Boehringer Ingelheim

Actelion Pharmaceuticals

Chronic Metabolic Disease Drug Segment by Type

Hyperlipidemia Drug

Hypertension Drug

High Blood Sugar Drug

High Uric Acid Drug

Chronic Metabolic Disease Drug Segment by Application

Hospital

Clinic

Others

Chronic Metabolic Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Metabolic Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Metabolic Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Metabolic Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Chronic Metabolic Disease Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Chronic Metabolic Disease Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Chronic Metabolic Disease Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Chronic Metabolic Disease Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Chronic Metabolic Disease Drug Sales (tons) of Manufacturers (2021-2026) Table 7. Global Chronic Metabolic Disease Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Chronic Metabolic Disease Drug Revenue of Manufacturers (2021-2026) Table 9. Global Chronic Metabolic Disease Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Chronic Metabolic Disease Drug Average Price (US$/ton) of Manufacturers (2021-2026) Table 11. Global Chronic Metabolic Disease Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Chronic Metabolic Disease Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Chronic Metabolic Disease Drug, Product Type & Application Table 14. Global Chronic Metabolic Disease Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Chronic Metabolic Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Novartis Company Information Table 19. Novartis Business Overview Table 20. Novartis Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 21. Novartis Chronic Metabolic Disease Drug Product Portfolio Table 22. Novartis Recent Developments Table 23. Novo Nordisk Company Information Table 24. Novo Nordisk Business Overview Table 25. Novo Nordisk Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 26. Novo Nordisk Chronic Metabolic Disease Drug Product Portfolio Table 27. Novo Nordisk Recent Developments Table 28. Merck & Co. Inc Company Information Table 29. Merck & Co. Inc Business Overview Table 30. Merck & Co. Inc Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 31. Merck & Co. Inc Chronic Metabolic Disease Drug Product Portfolio Table 32. Merck & Co. Inc Recent Developments Table 33. Eli Lilly Company Information Table 34. Eli Lilly Business Overview Table 35. Eli Lilly Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 36. Eli Lilly Chronic Metabolic Disease Drug Product Portfolio Table 37. Eli Lilly Recent Developments Table 38. Pfizer Company Information Table 39. Pfizer Business Overview Table 40. Pfizer Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 41. Pfizer Chronic Metabolic Disease Drug Product Portfolio Table 42. Pfizer Recent Developments Table 43. GlaxoSmithKline plc Company Information Table 44. GlaxoSmithKline plc Business Overview Table 45. GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 46. GlaxoSmithKline plc Chronic Metabolic Disease Drug Product Portfolio Table 47. GlaxoSmithKline plc Recent Developments Table 48. Fresenius Kabi Company Information Table 49. Fresenius Kabi Business Overview Table 50. Fresenius Kabi Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 51. Fresenius Kabi Chronic Metabolic Disease Drug Product Portfolio Table 52. Fresenius Kabi Recent Developments Table 53. Daiichi Sankyo Company Information Table 54. Daiichi Sankyo Business Overview Table 55. Daiichi Sankyo Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 56. Daiichi Sankyo Chronic Metabolic Disease Drug Product Portfolio Table 57. Daiichi Sankyo Recent Developments Table 58. AstraZeneca plc Company Information Table 59. AstraZeneca plc Business Overview Table 60. AstraZeneca plc Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 61. AstraZeneca plc Chronic Metabolic Disease Drug Product Portfolio Table 62. AstraZeneca plc Recent Developments Table 63. Torrent Labs Company Information Table 64. Torrent Labs Business Overview Table 65. Torrent Labs Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 66. Torrent Labs Chronic Metabolic Disease Drug Product Portfolio Table 67. Torrent Labs Recent Developments Table 68. Regeneron Pharmaceuticals Company Information Table 69. Regeneron Pharmaceuticals Business Overview Table 70. Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 71. Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio Table 72. Regeneron Pharmaceuticals Recent Developments Table 73. Boehringer Ingelheim Company Information Table 74. Boehringer Ingelheim Business Overview Table 75. Boehringer Ingelheim Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 76. Boehringer Ingelheim Chronic Metabolic Disease Drug Product Portfolio Table 77. Boehringer Ingelheim Recent Developments Table 78. Actelion Pharmaceuticals Company Information Table 79. Actelion Pharmaceuticals Business Overview Table 80. Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 81. Actelion Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio Table 82. Actelion Pharmaceuticals Recent Developments Table 83. Global Chronic Metabolic Disease Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Chronic Metabolic Disease Drug Sales by Region (2021-2026) & (tons) Table 85. Global Chronic Metabolic Disease Drug Sales Market Share by Region (2021-2026) Table 86. Global Chronic Metabolic Disease Drug Sales by Region (2027-2032) & (tons) Table 87. Global Chronic Metabolic Disease Drug Sales Market Share by Region (2027-2032) Table 88. Global Chronic Metabolic Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2021-2026) Table 90. Global Chronic Metabolic Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2027-2032) Table 92. North America Chronic Metabolic Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 94. North America Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 95. North America Chronic Metabolic Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Chronic Metabolic Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Chronic Metabolic Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 99. Europe Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 100. Europe Chronic Metabolic Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Chronic Metabolic Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Chronic Metabolic Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 104. Asia Pacific Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 105. Asia Pacific Chronic Metabolic Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Chronic Metabolic Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Chronic Metabolic Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 109. South America Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 110. South America Chronic Metabolic Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Chronic Metabolic Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Chronic Metabolic Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 114. Middle East and Africa Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 115. Middle East and Africa Chronic Metabolic Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Chronic Metabolic Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Chronic Metabolic Disease Drug Sales by Type (2021-2026) & (tons) Table 118. Global Chronic Metabolic Disease Drug Sales by Type (2027-2032) & (tons) Table 119. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2021-2026) Table 120. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2027-2032) Table 121. Global Chronic Metabolic Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Chronic Metabolic Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2021-2026) Table 124. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2027-2032) Table 125. Global Chronic Metabolic Disease Drug Price by Type (2021-2026) & (US$/ton) Table 126. Global Chronic Metabolic Disease Drug Price by Type (2027-2032) & (US$/ton) Table 127. Global Chronic Metabolic Disease Drug Sales by Application (2021-2026) & (tons) Table 128. Global Chronic Metabolic Disease Drug Sales by Application (2027-2032) & (tons) Table 129. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2021-2026) Table 130. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2027-2032) Table 131. Global Chronic Metabolic Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Chronic Metabolic Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2021-2026) Table 134. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2027-2032) Table 135. Global Chronic Metabolic Disease Drug Price by Application (2021-2026) & (US$/ton) Table 136. Global Chronic Metabolic Disease Drug Price by Application (2027-2032) & (US$/ton) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Chronic Metabolic Disease Drug Distributors List Table 140. Chronic Metabolic Disease Drug Customers List Table 141. Chronic Metabolic Disease Drug Industry Trends Table 142. Chronic Metabolic Disease Drug Industry Drivers Table 143. Chronic Metabolic Disease Drug Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Chronic Metabolic Disease Drug Product Image Figure 5. Global Chronic Metabolic Disease Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Chronic Metabolic Disease Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Chronic Metabolic Disease Drug Sales (2021-2032) & (tons) Figure 8. Global Chronic Metabolic Disease Drug Average Price (US$/ton) & (2021-2032) Figure 9. Hyperlipidemia Drug Product Image Figure 10. Hypertension Drug Product Image Figure 11. High Blood Sugar Drug Product Image Figure 12. High Uric Acid Drug Product Image Figure 13. Hospital Product Image Figure 14. Clinic Product Image Figure 15. Others Product Image Figure 16. Global Chronic Metabolic Disease Drug Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Chronic Metabolic Disease Drug, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Chronic Metabolic Disease Drug Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Chronic Metabolic Disease Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Chronic Metabolic Disease Drug Sales by Region in 2025 Figure 22. Global Chronic Metabolic Disease Drug Revenue by Region in 2025 Figure 23. North America Chronic Metabolic Disease Drug Market Size by Country in 2025 Figure 24. North America Chronic Metabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 25. North America Chronic Metabolic Disease Drug Revenue Market Share by Country (2021-2032) Figure 26. United States Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Chronic Metabolic Disease Drug Market Size by Country in 2025 Figure 30. Europe Chronic Metabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 31. Europe Chronic Metabolic Disease Drug Revenue Market Share by Country (2021-2032) Figure 32. Germany Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Chronic Metabolic Disease Drug Market Size by Country in 2025 Figure 43. Asia Pacific Chronic Metabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Chronic Metabolic Disease Drug Revenue Market Share by Country (2021-2032) Figure 45. China Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Chronic Metabolic Disease Drug Market Size by Country in 2025 Figure 54. South America Chronic Metabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 55. South America Chronic Metabolic Disease Drug Revenue Market Share by Country (2021-2032) Figure 56. Brazil Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Chronic Metabolic Disease Drug Market Size by Country in 2025 Figure 60. Middle East and Africa Chronic Metabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Chronic Metabolic Disease Drug Revenue Market Share by Country (2021-2032) Figure 62. Egypt Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Chronic Metabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2021-2032) Figure 68. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2021-2032) Figure 69. Global Chronic Metabolic Disease Drug Price (US$/ton) by Type (2021-2032) Figure 70. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2021-2032) Figure 71. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2021-2032) Figure 72. Global Chronic Metabolic Disease Drug Price (US$/ton) by Application (2021-2032) Figure 73. Chronic Metabolic Disease Drug Value Chain Figure 74. Chronic Metabolic Disease Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Chronic Metabolic Disease Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Hyperlipidemia Drug
  • Hypertension Drug
  • High Blood Sugar Drug
  • High Uric Acid Drug
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis
  • Novo Nordisk
  • Merck & Co. Inc
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline plc
  • Fresenius Kabi
  • Daiichi Sankyo
  • AstraZeneca plc
  • Torrent Labs
  • Regeneron Pharmaceuticals
  • Boehringer Ingelheim
  • Actelion Pharmaceuticals

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Chronic Metabolic Disease Drug Market Size (2021-2032)
  4. 2.2.2 Global Chronic Metabolic Disease Drug Sales (2021-2032)
  5. 2.2.3 Global Chronic Metabolic Disease Drug Market Average Price (2021-2032)
  6. 2.3 Chronic Metabolic Disease Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Hyperlipidemia Drug
  9. 2.3.3 Hypertension Drug
  10. 2.3.4 High Blood Sugar Drug
  11. 2.3.5 High Uric Acid Drug
  12. 2.4 Chronic Metabolic Disease Drug by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Hospital
  15. 2.4.3 Clinic
  16. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Chronic Metabolic Disease Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Chronic Metabolic Disease Drug Sales (tons) of Manufacturers (2021-2026)
  3. 3.3 Global Chronic Metabolic Disease Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Chronic Metabolic Disease Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Chronic Metabolic Disease Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Chronic Metabolic Disease Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Chronic Metabolic Disease Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Chronic Metabolic Disease Drug, Established Date
  9. 3.9 Global Chronic Metabolic Disease Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Novartis
  2. 4.1.1 Novartis Company Information
  3. 4.1.2 Novartis Business Overview
  4. 4.1.3 Novartis Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Novartis Chronic Metabolic Disease Drug Product Portfolio
  6. 4.1.5 Novartis Recent Developments
  7. 4.2 Novo Nordisk
  8. 4.2.1 Novo Nordisk Company Information
  9. 4.2.2 Novo Nordisk Business Overview
  10. 4.2.3 Novo Nordisk Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Novo Nordisk Chronic Metabolic Disease Drug Product Portfolio
  12. 4.2.5 Novo Nordisk Recent Developments
  13. 4.3 Merck & Co. Inc
  14. 4.3.1 Merck & Co. Inc Company Information
  15. 4.3.2 Merck & Co. Inc Business Overview
  16. 4.3.3 Merck & Co. Inc Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Merck & Co. Inc Chronic Metabolic Disease Drug Product Portfolio
  18. 4.3.5 Merck & Co. Inc Recent Developments
  19. 4.4 Eli Lilly
  20. 4.4.1 Eli Lilly Company Information
  21. 4.4.2 Eli Lilly Business Overview
  22. 4.4.3 Eli Lilly Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Eli Lilly Chronic Metabolic Disease Drug Product Portfolio
  24. 4.4.5 Eli Lilly Recent Developments
  25. 4.5 Pfizer
  26. 4.5.1 Pfizer Company Information
  27. 4.5.2 Pfizer Business Overview
  28. 4.5.3 Pfizer Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Pfizer Chronic Metabolic Disease Drug Product Portfolio
  30. 4.5.5 Pfizer Recent Developments
  31. 4.6 GlaxoSmithKline plc
  32. 4.6.1 GlaxoSmithKline plc Company Information
  33. 4.6.2 GlaxoSmithKline plc Business Overview
  34. 4.6.3 GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 GlaxoSmithKline plc Chronic Metabolic Disease Drug Product Portfolio
  36. 4.6.5 GlaxoSmithKline plc Recent Developments
  37. 4.7 Fresenius Kabi
  38. 4.7.1 Fresenius Kabi Company Information
  39. 4.7.2 Fresenius Kabi Business Overview
  40. 4.7.3 Fresenius Kabi Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Fresenius Kabi Chronic Metabolic Disease Drug Product Portfolio
  42. 4.7.5 Fresenius Kabi Recent Developments
  43. 4.8 Daiichi Sankyo
  44. 4.8.1 Daiichi Sankyo Company Information
  45. 4.8.2 Daiichi Sankyo Business Overview
  46. 4.8.3 Daiichi Sankyo Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Daiichi Sankyo Chronic Metabolic Disease Drug Product Portfolio
  48. 4.8.5 Daiichi Sankyo Recent Developments
  49. 4.9 AstraZeneca plc
  50. 4.9.1 AstraZeneca plc Company Information
  51. 4.9.2 AstraZeneca plc Business Overview
  52. 4.9.3 AstraZeneca plc Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AstraZeneca plc Chronic Metabolic Disease Drug Product Portfolio
  54. 4.9.5 AstraZeneca plc Recent Developments
  55. 4.10 Torrent Labs
  56. 4.10.1 Torrent Labs Company Information
  57. 4.10.2 Torrent Labs Business Overview
  58. 4.10.3 Torrent Labs Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Torrent Labs Chronic Metabolic Disease Drug Product Portfolio
  60. 4.10.5 Torrent Labs Recent Developments
  61. 4.11 Regeneron Pharmaceuticals
  62. 4.11.1 Regeneron Pharmaceuticals Company Information
  63. 4.11.2 Regeneron Pharmaceuticals Business Overview
  64. 4.11.3 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio
  66. 4.11.5 Regeneron Pharmaceuticals Recent Developments
  67. 4.12 Boehringer Ingelheim
  68. 4.12.1 Boehringer Ingelheim Company Information
  69. 4.12.2 Boehringer Ingelheim Business Overview
  70. 4.12.3 Boehringer Ingelheim Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Boehringer Ingelheim Chronic Metabolic Disease Drug Product Portfolio
  72. 4.12.5 Boehringer Ingelheim Recent Developments
  73. 4.13 Actelion Pharmaceuticals
  74. 4.13.1 Actelion Pharmaceuticals Company Information
  75. 4.13.2 Actelion Pharmaceuticals Business Overview
  76. 4.13.3 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio
  78. 4.13.5 Actelion Pharmaceuticals Recent Developments
5 Global Chronic Metabolic Disease Drug Market Scenario by Region
  1. 5.1 Global Chronic Metabolic Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Chronic Metabolic Disease Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Chronic Metabolic Disease Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Chronic Metabolic Disease Drug Sales by Region: 2027-2032
  5. 5.3 Global Chronic Metabolic Disease Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Chronic Metabolic Disease Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Chronic Metabolic Disease Drug Revenue by Region: 2027-2032
  8. 5.4 North America Chronic Metabolic Disease Drug Market Facts & Figures by Country
  9. 5.4.1 North America Chronic Metabolic Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Chronic Metabolic Disease Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Chronic Metabolic Disease Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Chronic Metabolic Disease Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Chronic Metabolic Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Chronic Metabolic Disease Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Chronic Metabolic Disease Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Chronic Metabolic Disease Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Chronic Metabolic Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Chronic Metabolic Disease Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Chronic Metabolic Disease Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Chronic Metabolic Disease Drug Market Facts & Figures by Country
  41. 5.7.1 South America Chronic Metabolic Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Chronic Metabolic Disease Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Chronic Metabolic Disease Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Chronic Metabolic Disease Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Chronic Metabolic Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Chronic Metabolic Disease Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Chronic Metabolic Disease Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Chronic Metabolic Disease Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Chronic Metabolic Disease Drug Sales by Type (2021-2032) & (tons)
  3. 6.1.2 Global Chronic Metabolic Disease Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Chronic Metabolic Disease Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Chronic Metabolic Disease Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Chronic Metabolic Disease Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Chronic Metabolic Disease Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Chronic Metabolic Disease Drug Sales by Application (2021-2032) & (tons)
  3. 7.1.2 Global Chronic Metabolic Disease Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Chronic Metabolic Disease Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Chronic Metabolic Disease Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Chronic Metabolic Disease Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Chronic Metabolic Disease Drug Value Chain Analysis
  2. 8.1.1 Chronic Metabolic Disease Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Chronic Metabolic Disease Drug Production Mode & Process
  5. 8.2 Chronic Metabolic Disease Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Chronic Metabolic Disease Drug Distributors
  8. 8.2.3 Chronic Metabolic Disease Drug Customers
9 Global Chronic Metabolic Disease Drug Analyzing Market Dynamics
  1. 9.1 Chronic Metabolic Disease Drug Industry Trends
  2. 9.2 Chronic Metabolic Disease Drug Industry Drivers
  3. 9.3 Chronic Metabolic Disease Drug Industry Opportunities and Challenges
  4. 9.4 Chronic Metabolic Disease Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst